CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma (NCT06617286) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
United States21 participantsStarted 2026-12-01
Plain-language summary
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Who can participate
Age range6 Years – 29 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between ≥ 6 and ≤ 29.99 years at the time of consent.
* Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
* Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:
Induction failure Progressive disease Disease relapse (1st, 2nd or 3rd)
* Confirmatory re-biopsy of relapse/refractory/persistent CD30+ cHL prior to study entry.
* Risk Factors: Patient must meet 2 or more of the established risk factors:
Performance score (Karnofsky/Lansky) \<;90% Time from diagnosis to first relapse of \<1 year Extra nodal involvement at the time of relapse/progression High baseline metabolic tumor volume (MTV, \>60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction
Exclusion Criteria:
* not meeting the inclusion criteria
What they're measuring
1
Safety of administering CAR T-cells
Timeframe: 2 years
2
Feasibility of Central Manufacturing of CAR T-cells